
- /
- Supported exchanges
- / US
- / ASMB.NASDAQ
Assembly Biosciences Inc (ASMB NASDAQ) stock market data APIs
Assembly Biosciences Inc Financial Data Overview
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study. The company also develops ABI-7423, an oral broad-spectrum non-nucleoside polymerase inhibitor that targets transplant-related herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Assembly Biosciences Inc data using free add-ons & libraries
Get Assembly Biosciences Inc Fundamental Data
Assembly Biosciences Inc Fundamental data includes:
- Net Revenue: 32 154 K
- EBITDA: -44 502 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: -1.6
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Assembly Biosciences Inc News

Assembly Biosciences Says First Participant Dosed in Phase 1b Study of HSV Drug ABI-1179
Assembly Biosciences (ASMB) said Monday the first participant has been dosed in the phase 1b portion PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...


Assembly Bio reports positive results from HBV drug trial
SOUTH SAN FRANCISCO - Assembly Biosciences, Inc. (NASDAQ:ASMB), a $131 million market cap biotech company, announced positive topline results from its Phase 1b study of ABI-4334, an investigational ca...

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B
– Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final 400 mg cohort – – Mean plasma HBV DNA reductions of...

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B
Assembly Biosciences, Inc. – Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final 400 mg cohort – – Mean ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.